CTIS2023-505788-35-00进行中（未招募）1 期
Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM)
Fakultni Nemocnice Hradec Kralove0 个研究点目标入组 73 人开始时间: 2023年5月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 73
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age = 18 years - 70 years, Ability to understand the nature and course of the study and sign written informed consent to participate in the study., Ability and willingness to complete study visit and commute to study center., Diagnosis of primary immune thrombocytopenia., Platelets count below 80x109/l (after termination or on corticotherapy) and fulfillment of the indication for therapy (bleeding, need for anticoagulation, constitutional symptoms, documented refractoriness when stopping corticoids, etc.)., Previous corticosteroid therapy lasting at least 14 days (pulse or continuous), after which, according to the doctor's decision, it is necessary/appropriate to continue ITP therapy., Women of childbearing potential must have a negative pregnancy test (from blood serum) and use effective methods of contraception before starting treatment., For women of childbearing potential: Willingness to prevent pregnancy and breast-feeding during treatment and for 12 months after the last dose of rituximab, using at least one of the highly reliable methods of contraception. For men: Willingness to prevent paternity during treatment and for the next 90 days after stopping mycophenolate treatment.
排除标准
- •Severe bleeding (grade 2 or more according to CTCAE), which requires a more intensive approach (hospitalization, IVIG)., Active cancer in the last 5 years, 11.Previous therapy: •Previous rituximab therapy in the last 12 months. •IVIG therapy or plasmapheresis in the last 28 days before the 1st study treatment administration (visit M1D1). •TPO-RA therapy, fostamatinib, immunosuppressants (MMF, CSA) in the last 28 days before the 1st study treatment administration (visit M1D1). •Cytostatic therapy in the last 28 days before the 1st study treatment administration (visit M1D1)., Participation in a clinical study involving administration of investigational medicinal product within 3 months (or 5 half-terms, whichever is longer) prior to screening., Laboratory findings more than 1.5 x upper limit - ALT, AST, GMT, ALP, creatine, PT, aPTT., Uncontrolled arterial hypertension., Infectious disease in the last 14 days before starting the study treatment (visit M1D1)., Planned surgical procedure in the next 6 months, or until visit M6., Splenectomy in the last 3 months., The presence of another significant disease limiting therapy (liver disease, GIT disease, psychiatric disease /suicide, depression/, etc.), Contraindications to administered drugs (simultaneous use of contraindicated drugs, HIV, hepatitis, liver disease, etc.), Breastfeeding, pregnancy, trying to get pregnant, Myelodysplastic syndrome (MDS) or other abnormalities in the blood count, except for thrombocytopenia (a sternal puncture may be necessary to exclude MDS)., History of Thrombocytopenic thrombotic purpura (TTP), Hemolytic-uremic syndrome (HUS), antiphospholipid syndrome (AFS) or acquired hemophilia, Immunodeficiency, History of anaphylaxis
研究者
相似试验
已完成
1 期
A combination immunotherapy for the patients with advanced or metastatic solid cancersolid cancerJPRN-UMIN000020440Yamaguchi university Graduate School of Medicine17
Enrolling By Invitation
不适用
Treatment of patients with immune-related adverse events after checkpoint inhibitors with extracorporeal photopheresis (ECP): a retrospective analysis and translational studiesImmune-related adverse events (colitis, hepatitis, dermatitis, arthralgia) after treatment with immune checkpoint inhibitors (antibodies against PD-1, PD-L1 and CTLA4).DRKS00026642niversitätsklinikum Freiburg20
招募中
不适用
Development of new approaches for immunotherapy of non-small cell lung cancerC34Malignant neoplasm of bronchus and lungDRKS00029641Molekulare PneumologieUniversitätsklinikum Erlangen
已完成
不适用
Clinical trial of immunomodulatory therapy using anti-thymocyte globulin and pegfilgrastim for recently onset type 1 diabetesType 1 diabetesJPRN-UMIN000027070Toyama University12
进行中（未招募）
不适用
Modulation of the immune response in patients with pancreatic tubular carcinoma - MIS-MITEUCTR2008-006710-23-SIBlood Transfusion Centre of Slovenia